- Home
- LSAK vs OBIO Comparison
LSAK vs OBIO Comparison
Compare LSAK & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LSAK | OBIO |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.4M | 237.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LSAK | OBIO |
|---|---|---|
| Price | $4.34 | $4.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 30.7K | ★ 256.3K |
| Earning Date | 02-04-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $677,582,000.00 | $2,818,000.00 |
| Revenue This Year | $11.72 | $36.43 |
| Revenue Next Year | $9.09 | $2.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.48 | 6.46 |
| 52 Week Low | $3.39 | $2.20 |
| 52 Week High | $5.58 | $6.30 |
Technical Indicators
Market Signals| Indicator | LSAK | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 59.01 | 48.50 |
| Support Level | $4.26 | $4.07 |
| Resistance Level | $4.49 | $4.47 |
| Average True Range (ATR) | 0.17 | 0.27 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 71.43 | 35.10 |
Price Performance
Historical ComparisonAbout LSAK Lesaka Technologies Inc.
Lesaka Technologies Inc provides payment solutions, transaction processing solutions, and financial technologies. The company operates two reportable segments: Merchant and Consumer. The company operates mainly within South Africa. The Merchant segment that derives majority revenue includes activities related to the provision of goods and services provided to corporate and other juristic entities. It earns fees from processing activities performed for its customers and revenue generated from the distribution of prepaid airtime. The Consumer segment includes activities related to the provision of financial services to customers, including bank accounts, loans, and insurance products. The firm charges monthly administration fees for all bank accounts.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.